

Global Recombinant Cell Culture Supplements Market Report and Forecast 2023-2031

Market Report | 2023-07-18 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Recombinant Cell Culture Supplements Market Report and Forecast 2023-2031

Global Recombinant Cell Culture Supplements Market Outlook

The global recombinant cell culture supplements market was valued at USD 489.3 million in 2022, driven by the increasing demand for cell-based therapies across the globe. The market size is anticipated to grow at a CAGR of 7.7% during the forecast period of 2023-2031 to achieve a value of USD 951.3 million by 2031.

Recombinant Cell Culture Supplements: Introduction

Recombinant cell culture supplements play a crucial role in the development and growth of cells in laboratory settings. These supplements provide essential nutrients, growth factors, and other bioactive molecules necessary for optimal cell culture conditions. They are commonly used in various fields such as biopharmaceutical production, regenerative medicine, and research applications.

The introduction of recombinant cell culture supplements has revolutionized cell culture techniques by offering enhanced performance, consistency, and reproducibility compared to traditional animal-derived supplements. These products are derived from recombinant DNA technology, where specific genes are inserted into host cells to produce desired proteins or growth factors.

Key Trends in the Recombinant Cell Culture Supplements Market

One of the key trends in the field of recombinant cell culture supplements is the shift towards serum-free and animal component-free formulations. Traditional cell culture supplements often contain serum derived from animal sources, which can introduce variability and potential risks such as contamination and transmission of infectious agents. Serum-free and animal component-free supplements provide a safer and more controlled environment for cell culture, ensuring the reproducibility of results.

Overall, the field of recombinant cell culture supplements is witnessing a shift towards serum-free and animal component-free formulations, customization for specific cell types or applications, increased focus on quality control and regulatory compliance, and integration with advanced cell culture technologies. These trends reflect the ongoing efforts to improve cell culture

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

techniques, enhance reproducibility, and meet the evolving needs of various industries relying on cell-based research and production.

Recombinant Cell Culture Supplements Market Segmentations

Market Breakup by Product Type

- Recombinant Albumin (rAlbumin)
- Recombinant Insulin (rInsulin)
- Recombinant Epidermal Growth Factor (rEGF)
- Recombinant Interleukin Growth Factor (rILGF)
- Recombinant Transferrin (rTransferrin)
- Recombinant Trypsin (rTrypsin)
- Recombinant Insulin-like Growth Factor (rIGF)
- Recombinant Stem Cell Factor (rSCF)
- Recombinant Aprotinin (rAprotinin)
- Recombinant Lysozyme (rLysozyme)
- Others
- Recombinant Transforming Growth Factor (rTGF)
- Recombinant Insulin-Transferrin-Selenium-Ethanolamine (rITSE)
- Recombinant Platelet-Derived Growth Factor (rPDGF)
- Recombinant Leukemia Inhibitory Factor (rLIF)
- Others

Market Breakup by Application

- Regenerative Medicine
- Stem Cell Therapies
- Cell Therapies
- Gene Therapies
- Bio-Production
- Monoclonal Antibodies
- Recombinant Proteins
- Hormones
- Vaccines
- Other Biological Products

Market by Expression System

- Mammalian Expression System
- E. coli Expression System
- Yeast Expression System
- Others

Market Breakup by End User

- Academic and Research Institutions
- Biotechnology and Pharmaceutical Companies
- Others

Market Breakup by Region

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Recombinant Cell Culture Supplements Market Scenario

The market for recombinant cell culture supplements is experiencing significant growth and is driven by various factors such as the increasing demand for cell-based therapies, advancements in biopharmaceutical production, and the rising focus on precision medicine and personalized therapies. These supplements play a crucial role in providing the necessary components for optimal cell growth, viability, and productivity in various applications.

The market is witnessing a shift towards serum-free and animal component-free supplements, driven by the need for safer and more standardized cell culture conditions. This shift is particularly prominent in industries such as biopharmaceuticals, where stringent quality control and regulatory compliance are essential. Serum-free and animal component-free supplements offer improved reproducibility, reduced risk of contamination, and better control over cell culture parameters.

Overall, the market for recombinant cell culture supplements is poised for significant growth, driven by the increasing demand for cell-based therapies, advancements in biopharmaceutical production, customization for specific cell types and applications, adoption of advanced cell culture technologies, and expanding geographical presence.

Recombinant Cell Culture Supplements Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Abcam plc.
- Corning Incorporated
- BBI Solutions OEM Limited
- FUJIFILM Irvine Scientific, Inc.
- Gemini Bioproducts, LLC
- HiMedia Laboratories, LLC
- Kingfisher Biotech, Inc.
- Lonza Group AG
- Merck KGaA
- Novus Biologicals, LLC
- Thermo Fisher Scientific Inc.
- Invitria

*We at Expert Market Research

always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1□Preface
- 1.1□Objectives of the Study
- 1.2□Key Assumptions
- 1.3□Report Coverage - Key Segmentation and Scope
- 1.4□Research Methodology
- 2□Executive Summary
- 3□Global Recombinant Cell Culture Supplements Market Overview
- 3.1□Global Recombinant Cell Culture Supplements Market Historical Value (2016-2022)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3.2 Global Recombinant Cell Culture Supplements Market Forecast Value (2023-2031)
- 4 Global Recombinant Cell Culture Supplements Market Dynamics
 - 4.1 Market Drivers and Constraints
 - 4.2 SWOT Analysis
 - 4.3 Porter's Five Forces Model
 - 4.4 Key Demand Indicators
 - 4.5 Key Price Indicators
 - 4.6 Industry Events, Initiatives, and Trends
 - 4.7 Value Chain Analysis
- 5 Global Recombinant Cell Culture Supplements Market Segmentation
 - 5.1 Global Recombinant Cell Culture Supplements Market by Product Type
 - 5.1.1 Market Overview
 - 5.1.2 Recombinant Albumin (rAlbumin)
 - 5.1.3 Recombinant Insulin (rInsulin)
 - 5.1.4 Recombinant Epidermal Growth Factor (rEGF)
 - 5.1.5 Recombinant Interleukin Growth Factor (rILGF)
 - 5.1.6 Recombinant Transferrin (rTransferrin)
 - 5.1.7 Recombinant Trypsin (rTrypsin)
 - 5.1.8 Recombinant Insulin-like Growth Factor (rIGF)
 - 5.1.9 Recombinant Stem Cell Factor (rSCF)
 - 5.1.10 Recombinant Aprotinin (rAprotinin)
 - 5.1.11 Recombinant Lysozyme (rLysozyme)
 - 5.1.12 Others
 - 5.1.12.1 Recombinant Transforming Growth Factor (rTGF)
 - 5.1.12.2 Recombinant Insulin-Transferrin-Selenium-Ethanolamine (rITSE)
 - 5.1.12.3 Recombinant Platelet-Derived Growth Factor (rPDGF)
 - 5.1.12.4 Recombinant Leukemia Inhibitory Factor (rLIF)
 - 5.1.12.5 Others
 - 5.2 Global Recombinant Cell Culture Supplements Market by Application
 - 5.2.1 Market Overview
 - 5.2.2 Regenerative Medicine
 - 5.2.2.1 Stem Cell Therapies
 - 5.2.2.2 Cell Therapies
 - 5.2.2.3 Gene Therapies
 - 5.2.3 Bio-Production
 - 5.2.3.1 Monoclonal Antibodies
 - 5.2.3.2 Recombinant Proteins
 - 5.2.3.3 Hormones
 - 5.2.3.4 Vaccines
 - 5.2.3.5 Other Biological Products
 - 5.3 Global Recombinant Cell Culture Supplements Market by Expression System
 - 5.3.1 Market Overview
 - 5.3.2 Mammalian Expression System
 - 5.3.3 E. coli Expression System
 - 5.3.4 Yeast Expression System
 - 5.3.5 Others
 - 5.4 Global Recombinant Cell Culture Supplements Market by End User

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.4.1 Market Overview
- 5.4.2 Academic and Research Institutions
- 5.4.3 Biotechnology and Pharmaceutical Companies
- 5.4.4 Others
- 5.5 Global Recombinant Cell Culture Supplements Market by Region
 - 5.5.1 Market Overview
 - 5.5.2 North America
 - 5.5.3 Europe
 - 5.5.4 Asia Pacific
 - 5.5.5 Latin America
 - 5.5.6 Middle East and Africa
- 6 North America Recombinant Cell Culture Supplements Market
 - 6.1 Market Share by Country
 - 6.2 United States of America
 - 6.3 Canada
- 7 Europe Recombinant Cell Culture Supplements Market
 - 7.1 Market Share by Country
 - 7.2 United Kingdom
 - 7.3 Germany
 - 7.4 France
 - 7.5 Italy
 - 7.6 Others
- 8 Asia Pacific Recombinant Cell Culture Supplements Market
 - 8.1 Market Share by Country
 - 8.2 China
 - 8.3 Japan
 - 8.4 India
 - 8.5 ASEAN
 - 8.6 Australia
 - 8.7 Others
- 9 Latin America Recombinant Cell Culture Supplements Market
 - 9.1 Market Share by Country
 - 9.2 Brazil
 - 9.3 Argentina
 - 9.4 Mexico
 - 9.5 Others
- 10 Middle East and Africa Recombinant Cell Culture Supplements Market
 - 10.1 Market Share by Country
 - 10.2 Saudi Arabia
 - 10.3 United Arab Emirates
 - 10.4 Nigeria
 - 10.5 South Africa
 - 10.6 Others
- 11 Patent Analysis
 - 11.1 Analysis by Type of Patent
 - 11.2 Analysis by Publication year

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3□Analysis by Issuing Authority
- 11.4□Analysis by Patent Age
- 11.5□Analysis by CPC Analysis
- 11.6□Analysis by Patent Valuation
- 11.7□Analysis by Key Players

12□Grants Analysis

- 12.1□Analysis by year
- 12.2□Analysis by Amount Awarded
- 12.3□Analysis by Issuing Authority
- 12.4□Analysis by Grant Application
- 12.5□Analysis by Funding Institute
- 12.6□Analysis by NIH Departments
- 12.7□Analysis by Recipient Organization

13□Funding Analysis

- 13.1□Analysis by Funding Instances
- 13.2□Analysis by Type of Funding
- 13.3□Analysis by Funding Amount
- 13.4□Analysis by Leading Players
- 13.5□Analysis by Leading Investors
- 13.6□Analysis by Geography

14□Partnership and Collaborations Analysis

- 14.1□Analysis by Partnership Instances
- 14.2□Analysis by Type of Partnership
- 14.3□Analysis by Leading Players
- 14.4□Analysis by Geography

15□Regulatory Framework

- 15.1□Regulatory Overview
 - 15.1.1□US FDA
 - 15.1.2□EU EMA
 - 15.1.3□INDIA CDSCO
 - 15.1.4□JAPAN PMDA
 - 15.1.5□Others

16□Supplier Landscape

- 16.1□Abcam plc.
 - 16.1.1□Financial Analysis
 - 16.1.2□Product Portfolio
 - 16.1.3□Demographic Reach and Achievements
 - 16.1.4□Mergers and Acquisitions
 - 16.1.5□Certifications
- 16.2□Corning Incorporated
 - 16.2.1□Financial Analysis
 - 16.2.2□Product Portfolio
 - 16.2.3□Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.2.4 Mergers and Acquisitions
- 16.2.5 Certifications
- 16.3 BBI Solutions OEM Limited
 - 16.3.1 Financial Analysis
 - 16.3.2 Product Portfolio
 - 16.3.3 Demographic Reach and Achievements
 - 16.3.4 Mergers and Acquisitions
 - 16.3.5 Certifications
- 16.4 FUJIFILM Irvine Scientific, Inc.
 - 16.4.1 Financial Analysis
 - 16.4.2 Financial Portfolio
 - 16.4.3 Demographic Reach and Achievements
 - 16.4.4 Mergers and Acquisitions
 - 16.4.5 Certifications
- 16.5 Gemini Bioproducts, LLC
 - 16.5.1 Financial Analysis
 - 16.5.2 Product Portfolio
 - 16.5.3 Demographic Reach and Achievements
 - 16.5.4 Mergers and Acquisitions
 - 16.5.5 Certifications
- 16.6 HiMedia Laboratories, LLC
 - 16.6.1 Financial Analysis
 - 16.6.2 Product Portfolio
 - 16.6.3 Demographic Reach and Achievements
 - 16.6.4 Mergers and Acquisitions
 - 16.6.5 Certifications
- 16.7 Kingfisher Biotech, Inc.
 - 16.7.1 Financial Analysis
 - 16.7.2 Product Portfolio
 - 16.7.3 Demographic Reach and Achievements
 - 16.7.4 Mergers and Acquisitions
 - 16.7.5 Certifications
- 16.8 Lonza Group AG
 - 16.8.1 Financial Analysis
 - 16.8.2 Product Portfolio
 - 16.8.3 Demographic Reach and Achievements
 - 16.8.4 Mergers and Acquisitions
 - 16.8.5 Certifications
- 16.9 Merck KGaA
 - 16.9.1 Financial Analysis
 - 16.9.2 Product Portfolio
 - 16.9.3 Demographic Reach and Achievements
 - 16.9.4 Mergers and Acquisitions
 - 16.9.5 Certifications
- 16.10 Novus Biologicals, LLC
 - 16.10.1 Financial Analysis
 - 16.10.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.10.3 Demographic Reach and Achievements
- 16.10.4 Mergers and Acquisitions
- 16.10.5 Certifications
- 16.11 Thermo Fisher Scientific Inc.
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Mergers and Acquisitions
- 16.11.5 Certifications
- 16.12 InVitria
- 16.12.1 Financial Analysis
- 16.12.2 Product Portfolio
- 16.12.3 Demographic Reach and Achievements
- 16.12.4 Mergers and Acquisitions
- 16.12.5 Certifications
- 17 Global Recombinant Cell Culture Supplements Market - Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Global Recombinant Cell Culture Supplements Market Report and Forecast
2023-2031**

Market Report | 2023-07-18 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com